Admittedly, the numbers below from speciality pharma company Shield Therapeutics (STX) don't tell us much. Besides a lack of turnover, the numbers relate to the period prior to its February listing. The past six months for the company have been far more exciting.
Shield's primary product - Feraccru - is a treatment for iron deficiency in patients with inflammatory bowel disease. In February it became the first drug of its kind to be granted marketing approval in Europe and, by deploying some of the £32.5m raised on IPO, Shield's in-house commercial team has now started the rollout of the drug in the UK.
Feraccru is also currently undergoing two late-stage clinical trials in the US and management has suggested that, should the drug be granted approval stateside, its potential market size will quadruple to four million patients.
In addition to Feraccru, Shield is developing a treatment for dangerously high levels of potassium in the blood: a condition associated with chronic kidney disease. The drug, PT20, has recently achieved good late-stage clinical trial results, although one further study is required before marketing approval is sought.
Analysts at Liberum expect 2016 adjusted pre-tax losses of £17.9m, giving a loss per share of 16p.
SHIELD THERAPEUTICS (STX) | ||||
|---|---|---|---|---|
| ORD PRICE: | 170p | MARKET VALUE: | £184m | |
| TOUCH: | 165-175p | 12-MONTH HIGH: | 190p | LOW: 155p |
| DIVIDEND YIELD: | nil | PE RATIO: | na | |
| NET ASSET VALUE: | * | NET CASH: | £0.7m | |
| Year to 31 Dec | Turnover (£m) | Pre-tax profit (£m) | Earnings per share (p) | Dividend per share (p) |
|---|---|---|---|---|
| 2012 | nil | -3.5 | -6.8 | nil |
| 2013 | nil | -4.5 | -8.9 | nil |
| 2014 | nil | -13.4 | -40.0 | nil |
| 2015 | nil | -24.5 | -57.0 | nil |
| % change | - | - | - | - |
Ex-div:na Payment:na All pre-IPO figures *Negative shareholder funds | ||||
